TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sol-Gel Technologies ( (SLGL) ) just unveiled an announcement.
On November 20, 2025, Sol-Gel Technologies announced its financial results for the third quarter ending September 30, 2025, alongside significant corporate updates. The company is advancing its lead drug candidate SGT-610 for Gorlin syndrome and exploring its potential for treating high-frequency basal cell carcinoma, which could significantly increase its commercial potential. Sol-Gel also reported Health Canada’s approval of EPSOLAY and signed a new agreement with Viatris for its commercialization in Australia and New Zealand. Despite a net loss of $5.9 million for the quarter, Sol-Gel is optimistic about its strategic partnerships and future revenue streams, aiming for substantial growth by 2031.
The most recent analyst rating on (SLGL) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Sol-Gel Technologies stock, see the SLGL Stock Forecast page.
Spark’s Take on SLGL Stock
According to Spark, TipRanks’ AI Analyst, SLGL is a Neutral.
Sol-Gel Technologies’ stock score reflects significant financial performance challenges due to negative profitability and cash flow issues. Positive technical indicators offer some short-term optimism, but the lack of valuation appeal and guidance from earnings calls creates uncertainty. Strategic financial improvements and clearer future guidance would be needed to enhance the stock’s attractiveness.
To see Spark’s full report on SLGL stock, click here.
More about Sol-Gel Technologies
Sol-Gel Technologies Ltd. is a dermatology company focused on developing and commercializing treatments for rare and severe skin conditions. The company is known for its innovative products such as TWYNEO and EPSOLAY, which are topical treatments for acne and rosacea, respectively. Sol-Gel is actively expanding its market presence through partnerships and licensing agreements across various regions.
Average Trading Volume: 22,143
Technical Sentiment Signal: Buy
Current Market Cap: $100.4M
Learn more about SLGL stock on TipRanks’ Stock Analysis page.